Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bender Robert & Associates

Bender Robert & Associates lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 24,876 shares of the biopharmaceutical company’s stock after selling 5,262 shares during the period. Gilead Sciences comprises about 0.5% of Bender Robert & Associates’ portfolio, making the stock its 25th biggest position. Bender Robert & Associates’ holdings in Gilead Sciences were worth $2,015,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership grew its holdings in shares of Gilead Sciences by 324.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after acquiring an additional 13,764,169 shares during the period. Morgan Stanley boosted its position in Gilead Sciences by 11.5% during the fourth quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock worth $1,476,358,000 after purchasing an additional 1,780,489 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Gilead Sciences by 70.6% in the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Gilead Sciences by 14.8% in the third quarter. Bank of New York Mellon Corp now owns 15,421,436 shares of the biopharmaceutical company’s stock valued at $951,350,000 after buying an additional 1,987,058 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Gilead Sciences by 3.0% during the 1st quarter. Northern Trust Corp now owns 14,969,251 shares of the biopharmaceutical company’s stock worth $889,922,000 after buying an additional 430,810 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 1.2 %

NASDAQ:GILD traded down $0.77 during trading hours on Thursday, reaching $66.16. 6,391,849 shares of the company were exchanged, compared to its average volume of 7,307,334. The firm has a market cap of $82.37 billion, a price-to-earnings ratio of 14.87, a PEG ratio of 0.92 and a beta of 0.19. The stock has a 50 day simple moving average of $72.25 and a 200 day simple moving average of $76.66. Gilead Sciences, Inc. has a 52-week low of $65.90 and a 52-week high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same quarter in the previous year, the company earned $1.67 earnings per share. The company’s quarterly revenue was down 3.7% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a dividend of $0.77 per share. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.66%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is presently 68.44%.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 26th. UBS Group cut their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday. Mizuho lowered their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Finally, Barclays cut their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $84.71.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.